The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy (Q38259866)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 September 2017

1 reference

Europe PubMed Central

The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy (English)

1 reference

Europe PubMed Central

1 September 2017

0 references

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

Riccardo Bartoletti

object named as

Riccardo Bartoletti

6

0 references

Vincenzo Mirone

object named as

Vincenzo Mirone

7

0 references

Vincenzo Ficarra

1

object named as

Vincenzo Ficarra

1 reference

Europe PubMed Central

1 September 2017

author name string

Marta Rossanese

2

1 reference

Europe PubMed Central

1 September 2017

Michele Zazzara

3

1 reference

Europe PubMed Central

1 September 2017

Gianluca Giannarini

4

1 reference

Europe PubMed Central

1 September 2017

Maria Abbinante

5

1 reference

Europe PubMed Central

1 September 2017

Francesco Scaglione

8

1 reference

Europe PubMed Central

1 September 2017

publication date

1 December 2014

1 reference

Europe PubMed Central

1 September 2017

Current urology reports

1 reference

Europe PubMed Central

1 September 2017

15

1 reference

Europe PubMed Central

1 September 2017

12

1 reference

Europe PubMed Central

1 September 2017

463

1 reference

Europe PubMed Central

1 September 2017

https://scigraph.springernature.com/pub.10.1007/s11934-014-0463-9

0 references

The ageing male reproductive tract.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

The correlation between metabolic syndrome and prostatic diseases

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

The long-term outcome of medical therapy for BPH.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

A Widespread Population Study of Actual Medical Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia Across Europe and Beyond Official Clinical Guidelines

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0463-9

21 January 2018

Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH)?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25312251

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11934-014-0463-9

1 reference

Europe PubMed Central

1 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

1 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38259866&oldid=2118210740"